FDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis
FDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced that the U.S. Food and Drug Administration…
Read MoreFDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis
Bionova Launches New Process Development and Pilot Plant in Fremont
Bionova Launches New Process Development and Pilot Plant in Fremont Bionova Scientific, an Asahi Kasei company and boutique commercial-scale biologics contract development and manufacturing organization (CDMO), has officially announced the…
GeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication
GeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication GeneDx (Nasdaq: WGS), a leading innovator in genomic insights, has announced an expansion of its genetic…
Cadrenal Therapeutics Partners with Abbott for Pivotal Tecarfarin Study in HeartMate 3™ LVAD Patients
Cadrenal Therapeutics Partners with Abbott for Pivotal Tecarfarin Study in HeartMate 3™ LVAD Patients Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company specializing in the development of cardiovascular therapeutics,…
Epredia Secures FDA 510(k) Clearance for E1000 Dx™ Digital Pathology Solution
Epredia Secures FDA 510(k) Clearance for E1000 Dx™ Digital Pathology Solution Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), has announced…
Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products
Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products Parse Biosciences, a leading innovator in scalable and accessible single-cell sequencing technology, has reaffirmed its commitment to advancing its Evercode™ single-cell…
Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million
Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million Repligen Corporation (Nasdaq: RGEN), a leading life sciences company specializing in bioprocessing technology, has announced the acquisition of 908 Devices…
Shorla Oncology Expands U.S. Presence with New Sales & Market Access Teams
Shorla Oncology Expands U.S. Presence with New Sales & Market Access Teams Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, has officially launched a dedicated sales force and market access…
Medable Secures CNIL Approval, Paving the Way for Digital Clinical Trials in the EU
Medable Secures CNIL Approval, Paving the Way for Digital Clinical Trials in the EU Medable Inc., a global leader in clinical development technology, has reached a significant regulatory milestone with…
NationsBenefits® Emphasizes Nutrition-First GLP-1 Support for National Nutrition Month
NationsBenefits® Reinforces Nutrition-First Approach to GLP-1 Support During National Nutrition Month As National Nutrition Month brings attention to the critical role of healthy eating in disease prevention and overall wellness,…
FDA Grants Orphan & Rare Pediatric Status to NEU-001 for Hirschsprung Disease
FDA Grants Orphan & Rare Pediatric Status to NEU-001 for Hirschsprung Disease Neurenati Therapeutics Inc., a biotechnology company specializing in rare pediatric diseases, has announced a significant regulatory milestone. The…
Amylyx Reports Q4 and Full-Year 2024 Financial Results
Amylyx Reports Q4 and Full-Year 2024 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) recently released its financial results for the fourth quarter and full year ending…